U.S. FDA grants orphan drug designation to ADX-2191 from Aldeyra Therapeutics
August 05, 2021
The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.
© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Inflammation & Infection
Autoimmune uveitis targeted by AAV gene therapy
September 08, 2021
Investigators have found that 1 intravitreal injection of an adeno-associated virus encoding an immunosuppressive transgene, either HLA-G or eqIL-10, reduced the clinical and histologic inflammation in a well-established model of autoimmune uveitis.
Pearls for ocular surgical success in patients with chronic uveitis
July 21, 2021
While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
Shedding light on Horner’s syndrome
July 06, 2021
Investigators found that 56.4% of Horner’s syndrome cases resulted from a dangerous cause.
Considering antibiotics use in postoperative endophthalmitis
June 01, 2021
Whilst endophthalmitis following cataract surgery can lead to serious vision outcomes, there are ways of minimising the risk of it occurring whilst also being mindful of the need to prescribe antibiotics in a way that does not worsen antimicrobial resistance.
Looking at 10 years of dry eye disease flares
May 06, 2021
Dr Christopher Starr discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.
Uveitis: A leading and underestimated cause of visual morbidity in patients
March 29, 2021
Ophthalmologists are seeking improved treatment options for uveitis as epidemiological studies demonstrate the scope and sight-stealing burden of the disease.
Navigating COVID-19 with ophthalmic patients in the hospital setting
February 22, 2021
Experience at one ophthalmic practice in Bulgaria demonstrates that new operating procedures, technologies and good management can enable clinics to remain open and operate safely during the COVID-19 pandemic. Ophthalmic training and education should continue to be a priority.
Controlling postop pain, inflammation in cataract patients: drug delivery vs drops
December 10, 2020
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
Ophthalmic challenges in 2021: What to expect in the coming year
November 25, 2020
In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.